IMMUNOTHERAPY WITH INTERLEUKIN-2 AND SKIN CHANGES

被引：0
|
作者：
LARBRE, B
NICOLAS, JF
SARRET, Y
TOGNET, E
MERCATELLO, A
THIVOLET, J
机构：
[1] HOP EDOUARD HERRIOT,DERMATOL CLIN,PAVILLON R,PL ARSONVAL,F-69437 LYON 03,FRANCE
[2] HOP EDOUARD HERRIOT,SERV NEPHROL,F-69437 LYON 03,FRANCE
来源：
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 1993年 / 120卷 / 08期
关键词：
INTERLEUKIN-2; RENAL CARCINOMA; MALIGNANT MELANOMA;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
The cutaneous manifestations which follow the administration of recombinant interleukin-2 (rIL-2) are well known, but their nature and severity have not yet been fully studied. The authors report the dermatological changes observed in 12 patients treated with rIL-2 for renal cancer. The predominant lesion was generalized erythema followed by desquamation.
引用
收藏
页码：528 / 533
页数：6
相关论文
共 50 条
  • [41] DECREASE IN CHOLESTEROL LEVELS DURING THE IMMUNOTHERAPY OF CANCER WITH INTERLEUKIN-2
    LISSONI, P
    BRIVIO, F
    PITTALIS, S
    PEREGO, MS
    ARDIZZOIA, A
    MAURI, O
    BARNI, S
    CRISPINO, S
    TANCINI, G
    BRITISH JOURNAL OF CANCER, 1991, 64 (05) : 956 - 958
  • [42] Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy
    Stagg, J
    Lejeune, L
    Paquin, A
    Galipeau, J
    HUMAN GENE THERAPY, 2004, 15 (06) : 597 - 608
  • [43] Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis
    Dix, RD
    Cousins, SW
    CURRENT HIV RESEARCH, 2004, 2 (04) : 333 - 342
  • [44] Use of interleukin-2 in immunotherapy of human immunodeficiency virus infection
    Reier, A
    Mitsuyasu, RT
    BIODRUGS, 1998, 10 (03) : 215 - 225
  • [45] Local immunotherapy of purulent sinusitis by recombinant human interleukin-2
    Totolian, A
    Lavrenova, G
    Galkina, O
    Katinas, E
    Smirnov, M
    Buravtsova, N
    Aleshina, L
    5TH WORLD CONGRESS ON TRAUMA, SHOCK, INFLAMMATION AND SEPSIS: PATHOPHYSIOLOGY, IMMUNE CONSEQUENCES AND THERAPY, 2000, : 307 - 311
  • [46] INTERLEUKIN-2 RECEPTOR TARGETED IMMUNOTHERAPY - UPDATE AND ATTEMPT AT SYNTHESIS
    DIAMANTSTEIN, T
    VOLK, HD
    HAHN, HJ
    TILNEY, NL
    KUPIECWEGLINSKI, JW
    PROGRESS IN IMMUNOLOGY, VOL 7, 1989, : 619 - 626
  • [47] CANCER-IMMUNOTHERAPY USING LOCAL INTERLEUKIN-2 ADMINISTRATION
    BUBENIK, J
    INDROVA, M
    IMMUNOLOGY LETTERS, 1987, 16 (3-4) : 305 - 309
  • [48] IMMUNOTHERAPY BY A SLOW DELIVERY SYSTEM OF INTERLEUKIN-2 IN MICE MODELS
    MATSUOKA, J
    SAKAGAMI, K
    FUJIWARA, T
    ONODA, T
    IDANI, H
    GOCHI, A
    ORITA, K
    ACTA MEDICA OKAYAMA, 1993, 47 (02) : 79 - 84
  • [49] IMMUNOTHERAPY OF TUMORS WITH INTERLEUKIN-2 AND LYMPHOKINE ACTIVATED KILLER CELLS
    JOST, LM
    GMUR, J
    OELZ, O
    SAUTER, C
    STAHEL, RA
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1989, 119 (05) : 137 - 143
  • [50] Morphological changes of lymphocytes activated with interleukin-2
    Nano, R
    Barni, S
    Capelli, E
    HAEMATOLOGICA, 1996, 81 (01) : 93 - 94
12345